title: Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn's disease patient with the loss of response to scheduled adalimumab maintenance therapy: a case report.
abstract: A 21-year-old Caucasian man with a diagnosis of Crohn's disease (CD) at the age of 14 was admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) maintenance therapy. His symptoms remained virtually unchanged following high dose corticosteroid therapy. Seven days later, combination therapy with ADA plus intensive granulocyte/monocyte adsorptive apheresis (GMA) was initiated, which induced clinical remission. Therefore, combination therapy with ADA plus intensive GMA appears to be an effective therapeutic option for patients with severe CD while under scheduled ADA maintenance therapy.
authors.affiliation: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan.
authors.forename: Keiji
authors.initials: K
authors.lastname: Ozeki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tanida
authors.forename: Takashi
authors.initials: T
authors.lastname: Mizushima
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Mizoshita
authors.forename: Hironobu
authors.initials: H
authors.lastname: Tsukamoto
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Hirata
authors.forename: Kenji
authors.initials: K
authors.lastname: Murakami
authors.forename: Takaya
authors.initials: T
authors.lastname: Shimura
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kataoka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kamiya
authors.forename: Takashi
authors.initials: T
authors.lastname: Joh
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003113:Colonoscopy; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000188:drug therapy* / Q000628:therapy; D006098:Granulocytes; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007937:Leukapheresis; D047589:Leukocyte Reduction Procedures; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use; D019804:Mesalamine / Q000008:administration & dosage / Q000627:therapeutic use; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D009000:Monocytes; D010289:Parenteral Nutrition, Total; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D008795:Metronidazole; D019804:Mesalamine; D011239:Prednisolone; D015122:Mercaptopurine; D000068879:Adalimumab